RxDoctor Payments Data

Trevor Alverson, NP

Family · Dalton, GANPI 1184179558

Payments from drug & device makers

$11,283in general payments, 2019–2025

Across 507 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Boston Scientific$1K
  • Novartis$1K
  • AstraZeneca$1K
  • Amgen$832
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$784
  • plus $4K from 29 others

What the payments were for

  • Travel & lodging$6666%
  • Food & beverage$10,53393%
  • Education$841%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,283 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$21,137
Medicare patients
158
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$203,493
JardianceEmpagliflozin92$71,409
FarxigaDapagliflozin Propanediol78$63,006
EntrestoSacubitril/Valsartan57$60,036
XareltoRivaroxaban55$44,848
BrilintaTicagrelor54$27,693
Repatha SureclickEvolocumab22$13,351
OzempicSemaglutide11$9,959
Ranolazine ErRanolazine115$7,575
DapagliflozinDapagliflozin Propanediol11$5,294
Metoprolol Succinate162$1,543
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,329
Ezetimibe58$945
Rosuvastatin Calcium87$892
ClopidogrelClopidogrel Bisulfate93$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$544$203,493238 claims
AstraZenecaFarxiga, Brilinta$1,008$90,699132 claims
Boehringer IngelheimJardiance$257$71,40992 claims
NovartisEntresto$1,079$60,03657 claims
Johnson & JohnsonXarelto$2,350$44,84855 claims
Novo NordiskOzempic$641$9,95911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →